A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

Trial Profile

A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Lucitanib (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 04 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 04 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top